There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …

Introduction Limited data exist on direct-acting oral anticoagulants in morbidly obese
patients with venous thromboembolism (VTE). We compared clinical and health/economic …

Background Rivaroxaban is a first-line option for the management of venous
thromboembolism (VTE). However, limited data are available regarding its effectiveness in …

Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …

The pharmacokinetics of oral rivaroxaban are highly predictable and only affected to a
limited extent by bodyweight; therefore, dose adjustments for bodyweight are not required …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Study Objective Studies on the use of direct oral anticoagulants (DOACs) in obese patients
are limited. Current guidelines advise against DOAC use in patients with a body weight …

Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …

Abstract Background Direct oral anticoagulants (DOACs) are recommended in preference to
traditional anticoagulants (LMWH±warfarin) for treating acute venous thromboembolism …

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide.
Appropriate anticoagulation is crucial in the treatment and prevention of recurrent VTE …